New research indicates that patients who discontinue new weight-loss injections like Mounjaro or Wegovy tend to recover shed pounds at a significantly accelerated pace than those who stop traditional lifestyle programs.
Published data in a prominent health publication points out that while overweight people frequently drop a large proportion of their total mass while undergoing treatment, the mass is regained at an estimated rate of 0.8 kg per month once they quit.
"People purchasing these treatments need to be aware of the risk of quick weight regain when the therapy ends," stated researcher Dr. Susan Jebb.
This pace of recovery means a return to original mass within about 18 months.
Weighing Treatments
The research, which looked at dozens of trials involving thousands of participants, compared the outcomes of the injectable medications with older methods.
The team note that people who shed pounds through dieting typically experience a slower creep back—approximately 100 grams monthly—once they finish.
Understanding the Quick Rebound
Doctors believe the way of the injections is key to understanding the heightened weight return.
These medications imitate a natural hormone called glucagon-like peptide-1, which controls appetite.
"Artificially providing the hormone levels far above than normal may cause the system to generate a reduced amount of its endogenous hormone, and may also lessen sensitivity to its actions," noted Dr. Adam Collins, a nutrition researcher.
"Stopping of this hormone supplement means appetite is unsuppressed, making overeating a significant risk."
An Ongoing Condition?
Medical guidelines advise the jabs for individuals with obesity-related health risks, accompanied by prescribed lifestyle changes.
Many experts argue that, due to the high risk of relapse, the treatment might need to be ongoing.
This view is reinforced by drug manufacturers, who say that the findings "emphasize the persistent character of obesity," comparing it to managing conditions like diabetes.
Patient Experiences
Individuals who have stopped the medication report a intense return of hunger.
"It was like something flipping and I was suddenly ravenous," recalled one woman.
This challenge is exacerbated if individuals have not established permanent lifestyle or habit changes during treatment.
Significant Interest
Recent estimates show that millions of people in the UK have tried these injections in the last 12 months, with demand being substantial.
- Adoption is higher among females than males.
- The middle-aged demographic shows the greatest level of interest.
- Many access the medications through private prescriptions rather than the NHS.
Finally, clinicians caution that while the jabs are effective agents for weight loss, they are not a permanent fix and long-term success hinges on combined behavioural changes.
